CLINICAL PRACTICE

Starch safety in resuscitation – when will we ever learn?

A Parrish, M Blockman

Andy Parrish has an interest in evidence-based medicine, works in the Department of Internal Medicine, Frere and Cecilia Makiwane hospitals, East London, and is affiliated to Walter Sisulu University, Rhodes University and the University of Cape Town, South Africa.

Marc Blockman has an interest in drug policy and evidence-based medicine and works in the Department of Internal Medicine, Division of Clinical Pharmacology, Groote Schuur Hospital and University of Cape Town, South Africa.

Corresponding author: A Parrish (andygp@mweb.co.za)

The recent publication of several large well-conducted trials on hydroxyethyl starch (HES) has led to a re-examination of evidence for colloids in medicine. A Cochrane review[1] showed no mortality advantage from HES, albumin, modified gelatins or dextran when compared with crystalloids. A 2011 review of HES[2] raised concerns of increased harm, particularly with older HES formulations, and this concern was reiterated in a 2013 review.[3] In a recent editorial[4] it was suggested that the accrued evidence now allows us to declare that starches have reached the ‘end of the road’ in the care of critically ill patients with sepsis.

In such patients the baseline mortality rate can be as high as 40%.[5] Even assuming half that (20%), a relative risk of 1.09 gives an absolute mortality increase of 1.8%, or one extra death for every 56 high-risk patients prescribed HES as used in the underlying trials. The South African (SA) public sector spent R45 million on HES in 2011 (pharmaceutical directorate, personal communication). If HES was used in a similar way to that in the sepsis trials, this might mean several hundred excess deaths annually in this country alone.

The new trials

The CHEST study[6] compared 90-day mortality in 7 000 patients admitted to intensive care units (ICUs) and resuscitated with either 6% HES 130/0.4 or saline. The two groups had similar mortality rates, but more patients in the HES group required renal replacement therapy (7.0% v. 5.8%; relative risk (RR) 1.21, 95% confidence interval (CI) 1.00 - 1.45). Patients in the 6S study[7] had severe sepsis and were given 6% HES 130/0.42 or Ringer’s acetate. Mortality at 90 days in the 398 patients in the HES group was 51%, while it was 43% in the 400 assigned to Ringer’s acetate (RR 1.17, 95% CI 1.01 - 1.36). At 90 days, more patients in the HES group needed renal replacement therapy (22% v. 16%; RR 1.35, 95% CI 1.01 - 1.80).

The same pattern was seen in the 196-patient CRystmas study,[8] which was only powered to detect a difference in volumes infused between 6% HES 130/0.4 and saline in patients with sepsis. The product manufacturer was involved in the design, analysis and write-up of the study. The 90-day mortality was non-significantly higher in the HES group (40% v. 33% using intention to treat data; RR 1.2, 95% CI 0.83 - 1.74).

VISEP[9] (2008) compared the older 10% HES 200/0.5 with Ringer’s lactate in 537 patients with severe sepsis. Total HES volumes infused were high, with a median cumulative volume of 70 ml/kg, and the dose limit of 20 ml/kg/day was exceeded by more than 10% on at least one day in more than 38% of patients. The trial was stopped early because of increased renal failure and a trend to increased mortality in the HES group. Mortality at 90 days was 41% in the HES group and 33.9% in the control group (RR 1.21, 95% CI 0.97 - 1.51). Renal replacement therapy was required in 31% of the HES group and in 18.8% of controls (RR 1.66, 95% CI 1.22 - 2.25).

Further interesting studies await publication. The blinded 240-patient Basel study for the evaluation of starch infusion for septic patients (BaSES[10]) was completed in May 2011. The unblinded 3 000-patient CRISTAL trial[11] compared ‘any colloid’ with crystalloid. The latter trial was reported (International Symposium on Intensive Care and Emergency Medicine 2013) to show a statistically significant overall survival benefit from early colloid use, but the details await full publication and careful HES subgroup analysis.

New systematic reviews

There have been several recent high-quality systematic reviews (Table 1). The Cochrane review on colloids was updated in 2013.[12] The RR of death in 15 trials of HES was 1.10 (95% CI 1.02 - 1.19), and that in the Gattas review[13] (third-generation HES products) was 1.08 (95% CI 0.97 - 1.21). Most recently, Zarzychanski et al performed a high-quality systematic review of all HES products.[14] The mortality RR was 1.09 (1.02 - 1.17) after excluding seven early trials by Boldt et al., whose research corpus must be regarded with caution after multiple retractions.[15] The Haase review,[16] looking only at a highly defined subset of starch trials (high-quality trials, third-generation HES, sepsis), found a very similar RR of 1.11 but with an expected wider CI (1.00 - 1.23). ‘Multiple-look’ meta-analyses increase the risk of false-positive results, which was addressed in this review using trial sequential analysis (wider 95% CI 0.95 - 1.29). None of the other patient-relevant...
clinical endpoints, such as length of ICU stay, use of mechanical ventilation or presence of major bleeding, showed a statistically significant advantage of HES over crystalloids.

Renal harm
Both the Gattas\textsuperscript{[21]} and Zarychanski\textsuperscript{[21]} reviews found convincing evidence of renal harm. In Gattas et al’s review, there was a 27% relative increase in the need for renal replacement therapy in patients given HES compared with crystalloid (RR 1.27, 95% CI 1.10 - 1.46). The equivalent RR in the Zarychanski review was 1.32 (95% CI 1.15 - 1.50) where the control intervention was not always crystalloid.

Assessing the potential for harm
Formal assessment of harm is complex, and may be unfamiliar to clinicians without expertise in pharmaco-epidemiology. Convincing safety signals usually require large numbers in the numerator, and registration trials are underpowered for this. Patient numbers several times higher than those used in efficacy trials are required. Accrual of harms may not proceed at the same rate as benefits, so acute resuscitation trials with short-term endpoints will not detect harms taking weeks to accrue. An appropriate comparator is important – pooling trials where some control groups were given other colloids rather than crystalloids dilutes harm signals.

The 0.05 type I error rate used to measure the certainty of an effect is purported to have originated with Fischer\textsuperscript{[21]} and was adopted by the Food and Drug Administration (FDA)\textsuperscript{[15]} and other medicines regulators. It makes sense to minimise the probability of a false-positive statement when determining efficacy. However, do we need to be 95% sure of danger before avoiding a course of action? Table 2 illustrates the effect of changing type 1 error rates on statements of certainty.

Unlike the albumin controversy, where an earlier Cochrane review\textsuperscript{[21]} raised concerns about harm that were not confirmed in a subsequent large trial (SAFE\textsuperscript{[21]}), the current HES harm signal comes from information on more than 10 000 patients and is robust.

Scoring reviews versus keeping score of the number of reviews
Manufacturers react appropriately to safety concerns by commissioning reviews. Guidelines on assessing the quality of a systematic review exist.\textsuperscript{[16]} High-quality reviews are reliable if the underlying trials are unbiased, and if adequate patient numbers have accrued. A ‘review of reviews’ on HES raises some concerns.\textsuperscript{[16]} The authors identified 165 reviews published between 1976 and 2010, of which 7% contained a meta-analysis. Of the higher-quality reviews, 83% were not supportive of HES versus 20% of the lower-quality reviews. Of 124 positive reviews, 70 were written by only 14 experts, and 10 of these authors had identifiable potential conflicts of interest. An unsuspecting reader is more likely to encounter multiple low-quality positive reviews than the few high-quality ones. Simple repetition does not imply truth.

Identifying industry influence
It is helpful to identify reviews at risk of bias. Clues include finding authors with clear affiliations to HES manufacturers, reviews listing regulators. It makes sense to minimise the probability of a false-positive statement when determining efficacy. However, do we need to be 95% sure of danger before avoiding a course of action? Table 2 illustrates the effect of changing type 1 error rates on statements of certainty.

Unlike the albumin controversy, where an earlier Cochrane review\textsuperscript{[21]} raised concerns about harm that were not confirmed in a subsequent large trial (SAFE\textsuperscript{[21]}), the current HES harm signal comes from information on more than 10 000 patients and is robust.

Scoring reviews versus keeping score of the number of reviews
Manufacturers react appropriately to safety concerns by commissioning reviews. Guidelines on assessing the quality of a systematic review exist.\textsuperscript{[16]} High-quality reviews are reliable if the underlying trials are unbiased, and if adequate patient numbers have accrued. A ‘review of reviews’ on HES raises some concerns.\textsuperscript{[16]} The authors identified 165 reviews published between 1976 and 2010, of which 7% contained a meta-analysis. Of the higher-quality reviews, 83% were not supportive of HES versus 20% of the lower-quality reviews. Of 124 positive reviews, 70 were written by only 14 experts, and 10 of these authors had identifiable potential conflicts of interest. An unsuspecting reader is more likely to encounter multiple low-quality positive reviews than the few high-quality ones. Simple repetition does not imply truth.

Identifying industry influence
It is helpful to identify reviews at risk of bias. Clues include finding authors with clear affiliations to HES manufacturers, reviews listing

Table 1. Hydroxyethyl starch reviews

<table>
<thead>
<tr>
<th>Author</th>
<th>Date</th>
<th>Indication</th>
<th>HES type</th>
<th>Bias risk</th>
<th>Mortality RR (95% CI) No. of studies (total patients)</th>
<th>Renal harm* RR (95% CI) No. of studies (total patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hartog et al.\textsuperscript{[26]}</td>
<td>2011</td>
<td>80% elective surgery</td>
<td>130/0.4</td>
<td></td>
<td>Insufficient data 56</td>
<td></td>
</tr>
<tr>
<td>Perel et al. (Cochrane)\textsuperscript{[9]}</td>
<td>2013</td>
<td>‘Critically ill patients’</td>
<td>All</td>
<td>Low</td>
<td>1.10 (1.02 - 1.19) 15 (9 147)</td>
<td></td>
</tr>
<tr>
<td>Gattas et al.\textsuperscript{[3,24]}</td>
<td>2013</td>
<td>‘Acutely ill patients’</td>
<td>130/0.4 or 0.42</td>
<td>Low</td>
<td>1.08 (0.97 - 1.21) 10 (8 367)</td>
<td>1.27 (1.10 - 1.46) 6 (8 141)</td>
</tr>
<tr>
<td>Zarychanski et al.\textsuperscript{[21]}</td>
<td>2013</td>
<td>‘Critically ill patients’</td>
<td>All</td>
<td>Moderate</td>
<td>1.09 (1.02 - 1.17) 28 (10 290)</td>
<td>1.32 (1.15 - 1.50) 10 (9 258)</td>
</tr>
<tr>
<td>Haase et al.\textsuperscript{[24]}</td>
<td>2013</td>
<td>Sepsis</td>
<td>130/0.38 - 0.45</td>
<td>Low to moderate</td>
<td>1.11 (1.00 - 1.23) 4 (3 016)</td>
<td>1.36 (1.08 - 1.72) 5 (1 311)</td>
</tr>
</tbody>
</table>

*Renal harm measured as need for renal replacement therapy.

Table 2. Sensitivity analysis* of differences in type I error rate for a pooled effect size (mortality) from the three major trials (VISEP,\textsuperscript{[9]} CHEST,\textsuperscript{[6]} 6S\textsuperscript{[6]})

<table>
<thead>
<tr>
<th>Confidence interval</th>
<th>Relative risk 1.10</th>
<th>Risk difference 0.021</th>
<th>Statistically significant</th>
</tr>
</thead>
<tbody>
<tr>
<td>99%</td>
<td>0.990 - 1.225</td>
<td>-0.002 - 0.044</td>
<td>No</td>
</tr>
<tr>
<td>95%</td>
<td>1.015 - 1.194</td>
<td>0.003 - 0.038</td>
<td>Yes</td>
</tr>
<tr>
<td>90%</td>
<td>1.029 - 1.178</td>
<td>0.006 - 0.036</td>
<td>Yes</td>
</tr>
<tr>
<td>50%</td>
<td>1.071 - 1.132</td>
<td>0.015 - 0.027</td>
<td>Yes</td>
</tr>
<tr>
<td>33%</td>
<td>1.082 - 1.121</td>
<td>0.017 - 0.025</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*Renal harm measured as need for renal replacement therapy.

If VISEP, which contributes only 6.7% of the weight of the combined three trials, is omitted, for the remaining two trials the relative risk of death changes to 1.088, with a 95% CI from 0.997 to 1.187, and a 90% CI from 1.011 to 1.170.

*Corrected for publication bias.
a manufacturer as sponsor or originator of a review, and reviews looking at endpoints where the focus is on physiological variables or other short-term surrogate markers rather than patient-relevant clinical measures. Missing features often include a clearly defined trial search strategy, and a table listing inclusions and exclusions, and the reasons for these. Lack of power to detect harm even after study pooling may be underemphasised. Measure of internal validity (trial quality scores) may be absent, and control groups inappropriate. Pooling methods may be unusual or use methods that do not take account of differences in baseline prevalence and trial size.21 The introduction and discussion sections may contain non-scientific ‘emotive’ words and product trade names.

For example, a 2013 industry-associated review22 of 17 studies of HES in surgical patients found ‘no evidence of renal dysfunction’. Only 6 of these studies (a total of 437 patients) had a crystalloid comparator, trial quality was not formally reported, and there was no mention of HES in surgical patients found ‘no evidence of renal dysfunction’. With sepsis, and may increase the need for dialysis in resuscitation. With comprehensive data, it is difficult to justify ongoing use of these products.

Conflict of interest. The authors have no financial or intellectual conflict of interest.